Research analysts covering VYCOR MEDICAL.
Recent press releases and 8-K filings for VYCO.
Vycor Medical Releases Financial Results for Q3 and Nine Months Ended September 30, 2025
VYCO
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
- Vycor Medical, Inc. reported revenue of $513,792 for the three months ended September 30, 2025, an increase of 31% over the same period in 2024. For the nine months ended September 30, 2025, revenue was $1,446,523, up 28% from the prior year.
- The Vycor Medical division's revenue for the three months ended September 30, 2025, increased by 32%, primarily driven by growth in the US, while the nine-month growth of 29% was mainly from international markets.
- The company achieved a GAAP operating profit of $32,085 for the three months and $70,425 for the nine months ended September 30, 2025. Non-GAAP operating profit was $60,162 and $166,262 for the respective periods, representing substantial increases over 2024.
- Vycor Medical's GAAP net income (loss) available to common stockholders was $(157,249) for the three months and $(334,110) for the nine months ended September 30, 2025.
- Three new clinical papers involving Vycor’s ViewSite™ Brain Access System (VBAS) were published during Q3 2025, bringing the total peer-reviewed papers to 50, and a new clinical study on NovaVision’s NeuroEyeCoach validated its effectiveness for home-based or clinic-based use.
Nov 14, 2025, 4:48 PM
Vivani Medical Withdraws Cortigent Spin-Off Record Date
VYCO
M&A
New Projects/Investments
- Vivani Medical has temporarily withdrawn the record date for the spin-off of its subsidiary Cortigent due to delays caused by the U.S. federal government shutdown.
- The spin-off aims to better position Cortigent to accelerate development of its neurostimulation brain-computer interfaces, while allowing Vivani to focus on its drug implant business for chronic diseases.
- Cortigent's Orion Visual Cortical Prosthesis System, an investigational device for treating blindness, has received FDA Breakthrough Device designation and completed a 6-year Early Feasibility Study in 2025 with promising safety and efficacy results.
- Vivani Medical faces financial challenges, including ongoing losses, high leverage, and zero revenue growth over recent years, contributing to a cautious analyst outlook.
Oct 3, 2025, 6:08 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more